Investigational drug · Phase 2
ST101
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Glioblastoma, Melanoma Stage IV, Breast Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
6
Any phase or sponsor naming "ST101"
First trial start
2020
Jul 1, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ST101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Glioblastoma
- Melanoma Stage IV
- Breast Cancer
- Prostate Cancer
- Glioblastoma Multiforme
- GBM
- Brain Cancer
- Metastatic Breast Cancer
- Metastatic Melanoma
- Metastatic Prostate Cancer
Approved drugs for the same conditions: Breast cancer · Prostate cancer · Melanoma · Brain tumors (glioma) · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "ST101" as an intervention, largest first.
SystImmune Inc.Industry
NCT07857616 · 424 participants (planned) · Start Jul 30, 2026 · Primary completion Oct 2028
Drug: SI-B036 · For: Locally Advanced /Metastatic Solid Tumors; Locally Advanced / Metastatic Solid Tumors; Metastatic Solid Cancers and 5 more
Sites: New Haven, Connecticut; Orlando, Florida; Sarasota, Florida · 7 sites in all
SystImmune Inc.Industry
NCT07940881 · 400 participants (planned) · Start Aug 24, 2026 · Primary completion Nov 2028
Drug: SI-B037 · For: Locally Advanced /Metastatic Solid Tumors; Locally Advanced / Metastatic Solid Tumors; First in Human and 12 more
Sites: Houston, Texas
- Preliminary Efficacy and Safety Study of ST101 Plus Aricept in Alzheimer's DiseasePivotal-lookingCompleted
Sonexa Therapeutics, Inc.Industry
NCT00842816 · 210 participants · Start Feb 2009 · Primary completion May 2011
Drug: ST101; ST101 and 2 more · For: Alzheimer's Disease
Sites: Tucson, Arizona; Costa Mesa, California; Redlands, California · 30 sites in all
- Preliminary Efficacy and Safety Study of ST101 in Alzheimer's DiseasePivotal-lookingCompleted
Sonexa Therapeutics, Inc.Industry
NCT00842673 · 168 participants · Start Feb 2009 · Primary completion Sep 2010
Drug: ST101; ST101 and 2 more · For: Alzheimer's Disease
Sites: Costa Mesa, California; Redlands, California; San Diego, California · 18 sites in all
- A Phase 1-2 Study of ST101 in Patients With Advanced Solid TumorsActive, not recruiting
Sapience TherapeuticsIndustry
NCT04478279 · 125 participants · Start Jul 1, 2020 · Primary completion Dec 2026
Drug: ST101; Temozolomide · For: Glioblastoma; Melanoma Stage IV; Breast Cancer and 11 more
Sites: San Francisco, California; Denver, Colorado; Warrenville, Illinois · 11 sites in all
Sonexa Therapeutics, Inc.Industry
NCT01332695 · 25 participants · Start Apr 2011 · Primary completion Dec 2011
Drug: ST101; Placebo · For: Essential Tremor
Sites: Los Angeles, California
Newest research
PubMed records naming it or its code names, newest first.
- Clinical and molecular profile of Klebsiella pneumoniae bloodstream infections in a national referral hospital in the Philippines.
Francisco C, Dela Tonga A, Geganzo SM, et al. · IJID Reg 2026
- The persistence and transmission of mcr-mediated colistin resistance in E. coli from pigs, farmers, and farm environments after colistin withdrawal in Thailand.
Chumtong S, Surachat K, Pomwised R, et al. · One Health 2026
- Epidemiology, Resistance, and Virulence of Neonatal Klebsiella pneumoniae Isolates From a Tertiary Hospital in Tanzania.
Msanga DR, Minja CA, Härtel C, et al. · J Infect Dis 2026
- One health molecular epidemiology of carbapenem- and colistin-resistant Escherichia coli sequence types in humans, poultry, and the environment in Pakistan.
Qamar MU, Kariuki S, Zahra FT, et al. · Mol Biol Rep 2026
- Multi-species plasmids and K. pneumoniae clonal spread contribute to bla NDM outbreak across seven UK healthcare sites.
Duggan C, Brookfield C, Lawrie D, et al. · JAC Antimicrob Resist 2026
- Phenotypic and genomic characterization of antimicrobial resistance in Escherichia coli and Klebsiella spp. from livestock in Namibia.
Nangolo LN, Kakungu A, Musundi S, et al. · PLoS One 2026
Also in development for Glioblastoma
- Anlotinib hydrochlorideAL3818, CatequentenibPhase 312 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Alveolar Soft Part Sarcoma, Metastatic Colorectal Cancer, Endometrial Neoplasms
- L19TNFL19IL2, OnfekafuspPhase 310 trials
Philogen S.p.A. · Glioblastoma, Locally Advanced Basal Cell Carcinoma, Melanoma Stage III
- VebreltinibPLB1001Phase 36 trials
Avistone Biotechnology Co., Ltd. · Non-Small-Cell Lung Cancer, Glioblastoma, Non-Small Cell Lung Cancer
- VRT106Phase 33 trials
Guangzhou Virotech Pharmaceutical Co., Ltd. · Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Intrinsic Pontine Glioma, HCC
- INO-9012Phase 24 trials
Geneos Therapeutics · HCC, Glioblastoma, Urothelial Carcinoma
- AL58805Phase 22 trials
Advenchen Pharmaceuticals, LLC. · Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms
- AzeliragonPhase 22 trials
Cantex Pharmaceuticals · Glioblastoma
- INO-5401Phase 22 trials
Inovio Pharmaceuticals · Glioblastoma, Urothelial Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.